InvestSMART

Prana Biotechnology Limited (ASX: PBT) - Announcements

Current share price for PBT : $0.049 0.002 (4.26%)+

ASX company news and announcements for Prana Biotechnology Limited (PBT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prana Biotechnology Limited (PBT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prana Biotechnology Limited (PBT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prana Biotechnology Limited (PBT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Trading Halt 25 Feb 2008 9:12AM $0.695 $0.049 fallen by 92.95%
- Appendix 4D 15 Feb 2008 4:34PM $0.500 $0.049 fallen by 90.20%
- Appendix 4C - quarterly 31 Jan 2008 12:01PM $0.490 $0.049 fallen by 90%
- Prana provides update on Research and Development Program 20 Dec 2007 1:58PM $0.470 $0.049 fallen by 89.57%
- Final Patient Dosing in Phase 11a trial of PBT2 Completed 18 Dec 2007 10:52AM $0.400 $0.049 fallen by 87.75%
- Prana to Co-Host Expert Panel Discussion 6 Dec 2007 9:16AM $0.230 $0.049 fallen by 78.70%
- Positive Report From Independent Data Safety MonitoringBoard 29 Nov 2007 10:01AM $0.250 $0.049 fallen by 80.40%
- Prana Closes Approximately A$8 million Placement 1 Nov 2007 2:14PM $0.285 $0.049 fallen by 82.81%
- Appendix 4C - quarterly 31 Oct 2007 4:23PM $0.285 $0.049 fallen by 82.81%
- Prana Completes Enrollment in Phase 11a Trial of PBT2 24 Sep 2007 1:56PM $0.295 $0.049 fallen by 83.39%
- Prana to raise A$7m from Institutional and Prof. Investors 12 Sep 2007 10:17AM $0.300 $0.049 fallen by 83.67%
- Appendix 4E 31 Aug 2007 4:40PM $0.290 $0.049 fallen by 83.10%
- Implications of Metal Ion-Binding Studies 14 Aug 2007 10:46AM $0.310 $0.049 fallen by 84.19%
- Update on Phase 11a Trial of PBT2 in Alzheimer`s Patients 6 Aug 2007 9:41AM $0.320 $0.049 fallen by 84.69%
- Appendix 4C - quarterly 30 Jul 2007 4:38PM $0.295 $0.049 fallen by 83.39%
- Presents new key findings on PBT2 7 Jun 2007 9:18AM $0.350 $0.049 fallen by 86%
- Commitments Test Entity - Third Quarter Report 27 Apr 2007 4:48PM $0.365 $0.049 fallen by 86.58%
- Half Yearly Report & Half Year Accounts 28 Feb 2007 2:48PM $0.335 $0.049 fallen by 85.37%
- Commitments Test Entity - Second Quarter Report 31 Jan 2007 4:50PM $0.380 $0.049 fallen by 87.11%
- Dosing Commenced in Phase 11a PBT2 Trial 20 Dec 2006 9:57AM $0.385 $0.049 fallen by 87.27%
- Prana raises A$7.8M to Fund Phase IIa Clinical Trial of PBT2 21 Nov 2006 10:06AM $0.445 $0.049 fallen by 88.99%
- Trading Halt 17 Nov 2006 11:46AM $0.430 $0.049 fallen by 88.60%
- Commitments Test Entity - First Quarter Report 30 Oct 2006 5:12PM $0.380 $0.049 fallen by 87.11%
- Regulatory Approval to Start PBT2 Phase 11a Clinical Trial 5 Oct 2006 10:02AM $0.495 $0.049 fallen by 90.10%
- Preliminary Final Report 7 Sep 2006 4:56PM $0.375 $0.049 fallen by 86.93%

276 - 300 of 331 results

Page 12 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.